Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
At close: Apr 28, 2026, 4:00 PM EDT
7.50
+0.26 (3.59%)
After-hours: Apr 28, 2026, 7:48 PM EDT
Relmada Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Relmada Therapeutics stock have an average target of 12.4, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 71.27% from the current stock price of 7.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 24, 2026.
Analyst Ratings
The average analyst rating for Relmada Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $12 | Buy | Initiates | $12 | +65.75% | Mar 24, 2026 |
| Mizuho | Mizuho | Buy Maintains $10 → $19 | Buy | Maintains | $10 → $19 | +162.43% | Mar 20, 2026 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +93.37% | Mar 2, 2026 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $8 | Hold → Buy | Upgrades | $8 | +10.50% | Jan 23, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +24.31% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.78
from -1.45
EPS Next Year
-0.97
from -0.78
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.63 | -0.63 | ||||||
| Avg | -0.78 | -0.97 | ||||||
| Low | -0.89 | -1.22 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.